Loading...
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy
Gray, Phillip N. Vuong, Huy Tsai, Pei Lu, Hsaio-Mei Mu, Wenbo Hsuan, Vickie Hoo, Jayne Shah, Swati Uyeda, Lisa Fox, Susanne
Gray, Phillip N.
Vuong, Huy
Tsai, Pei
Lu, Hsaio-Mei
Mu, Wenbo
Hsuan, Vickie
Hoo, Jayne
Shah, Swati
Uyeda, Lisa
Fox, Susanne
Citations
Altmetric:
Genre
Journal article
Date
2016-09-08
Advisor
Committee member
Department
Cancer and Cellular Biology
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.18632/oncotarget.11910
Abstract
The development of targeted therapies for both germline and somatic DNA mutations has increased the need for molecular profiling assays to determine the mutational status of specific genes. Moreover, the potential of off-label prescription of targeted therapies favors classifying tumors based on DNA alterations rather than traditional tissue pathology. Here we describe the analytical validation of a custom probe-based NGS tumor panel, TumorNext, which can detect single nucleotide variants, small insertions and deletions in 142 genes that are frequently mutated in somatic and/or germline cancers. TumorNext also detects gene fusions and structural variants, such as tandem duplications and inversions, in 15 frequently disrupted oncogenes and tumor suppressors. The assay uses a matched control and custom bioinformatics pipeline to differentiate between somatic and germline mutations, allowing precise variant classification. We tested 170 previously characterized samples, of which > 95% were formalin-fixed paraffin embedded tissue from 8 different cancer types, and highlight examples where lack of germline status may have led to the inappropriate prescription of therapy. We also describe the validation of the Affymetrix OncoScan platform, an array technology for high resolution copy number variant detection for use in parallel with the NGS panel that can detect single copy amplifications and hemizygous deletions. We analyzed 80 previously characterized formalin-fixed paraffin-embedded specimens and provide examples of hemizygous deletion detection in samples with known pathogenic germline mutations. Thus, the TumorNext combined approach of NGS and OncoScan potentially allows for the identification of the “second hit” in hereditary cancer patients.
Description
Citation
Gray PN, Vuong H, Tsai P, Lu H, Mu W, Hsuan V, et al. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget. 2016 Aug 8;7:68206-68228. doi:10.18632/oncotarget.11910.
Citation to related work
Impact Journals
Has part
Oncotarget, Vol. 7, No. 42
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu